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Perspectives
D
espite the signiﬁ  cant 
progress in increasing our 
understanding of the immune 
mechanisms of multiple sclerosis (MS), 
in improving clinical classiﬁ  cation and 
brain imaging, and in developing new 
treatments, the factors that determine 
the course of the disease are mostly 
unknown [1]. Currently, it is nearly 
impossible to predict the course of 
MS, its severity in terms of disability 
progression, or when a relapse will 
happen. 
The most commonly used disease-
modifying therapies are interferon 
β (IFNβ) [2] and glatiramer acetate 
[2,3]. Despite initial excitement, 
these therapies have beneﬁ  cial effects 
in some, but not all, patients [2,3]. 
Because of the potential favorable 
effects of these therapies, it has been 
suggested that they should be initiated 
as early as possible to maximize 
neuroprotection [4]. Additionally, 
it has been recommended that 
patients should be monitored closely 
to determine whether and when it 
is necessary to modify treatment in 
order to maximize the beneﬁ  t [5]. The 
recommended monitoring is based on 
annual rate of relapses, neurological 
deterioration, and evidence of disease 
activity on brain magnetic resonance 
imaging scans. However, given the 
destructive nature of the disease, if we 
rely solely on clinical or radiological 
manifestations (such as a relapse or a 
new lesion on a scan) to determine a 
patient’s response to therapy, we will 
probably be responding too late. 
Gene Expression Patterns in 
Affected Organs 
The diagnosis and management of 
disease could be transformed thanks to 
the completion of the 
human genome project, 
the availability of 
sequence information 
for nearly every gene, 
and the advent of 
novel high throughput 
technologies 
(microarrays—see 
Glossary) that allow 
parallel proﬁ  ling of 
thousands of genes. 
By deﬁ  nition, nearly 
every aspect of a disease 
phenotype should be 
represented in gene 
expression signatures 
of multiple genes in 
the affected organ. 
Indeed, studies that analyze affected 
tissues (mostly in cancer) clearly show 
that it is possible to predict prognosis, 
to identify new classes of diseases, and 
potentially to determine response to 
therapy [6,7,8]. 
In diseases that do not require tissue 
resection for diagnosis or therapy, it is 
rare to obtain tissues for analysis. This 
problem is even more pronounced 
in diseases like MS, in which the 
target organ is the very inaccessible 
brain and spinal cord. Despite these 
limitations, several groups used 
microarrays to analyze brain tissues 
obtained posthumously from patients 
who had MS and identiﬁ  ed genes that 
characterized either acute or chronic 
lesions [9,10,11]. However, although 
these studies identiﬁ  ed some potential 
genes that may be involved in the local 
pathogenesis of the disease, they did 
not produce any information that could 
be used for identifying biomarkers 
associated with disease activity. 
Diagnostic Peripheral 
Blood Mononuclear Cell Gene 
Expression Signatures
In MS, looking for markers of disease 
activity in the much more accessible 
peripheral blood does not require 
a signiﬁ  cant leap of faith. MS is an 
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Figure 1. Expression Levels of Three Genes in Patients Who 
Responded (Red) and Who Did Not Respond (Blue) to IFNβ
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autoimmune disease, and it is possible 
that some of the cells involved in the 
pathogenesis of the disease will be 
found in the bloodstream. Abnormal 
T cell populations have repeatedly 
been observed in the peripheral 
blood of patients with MS [12,13,14]. 
While these results supported looking 
at the easily accessible peripheral 
blood mononuclear cells (PBMCs) 
for potential markers that reﬂ  ect 
the disease, some doubts persisted. 
These revolved around two very strong 
arguments. The ﬁ  rst argument was that 
if the signal comes from a minority of 
the cells within the bloodstream it will 
be too low to be detected. The second 
was that interpersonal variability, added 
to the inherent noisy nature of gene 
expression data, will make the data 
impossible to reproduce. 
Fortunately, recent observations 
suggest that these doubts are 
unfounded. Bomprezzi et al. [15] 
determined that gene expression 
patterns can distinguish patients 
with MS from controls and suggested 
that at least some of the differences 
identiﬁ  ed were derived from activated 
T cells. Achiron et al. [16] analyzed 
the expression of 12,000 genes in 
patients with relapsing–remitting 
MS. Gene expression patterns 
clearly distinguished patients with 
MS from controls as well as relapse 
from remission. Mandel et al. [17] 
compared patients with systemic lupus 
erythematosus and MS, and identiﬁ  ed 
a common autoimmunity signature as 
well as disease-speciﬁ  c gene expression 
signatures. Interestingly, similar 
ﬁ  ndings were recently described for 
pulmonary arterial hypertension [18]. 
Could PBMC Gene Expression 
Signatures Be Used for Predicting 
Response to Therapy? 
Weinstock-Guttman et al. [19] analyzed 
the acute transcriptional response 
of 4,000 genes in peripheral blood 
lymphocytes to IFNβ. They identiﬁ  ed 
increases in known interferon-
inducible genes, and in genes involved 
in antiviral activity and interferon 
signaling. Using complementary DNA 
(cDNA) arrays, Sturzebecher et al. [20] 
identiﬁ  ed gene expression signatures 
that distinguished IFNβ responders 
from nonresponders. 
And now, in a new study published 
in last month’s PLoS Biology, Baranzini 
et al. [21] provide compelling 
evidence that these PBMC gene 
expression signatures can be used to 
predict response to therapy (Figure 
1). They studied the expression of 
70 genes selected for their presumed 
biological function in 52 patients 
with MS, followed up for at least two 
years after initiation of IFNβ therapy. 
Instead of using microarrays that 
carry probes for thousands of genes, 
they chose to use real-time PCR. This 
method is highly sensitive, speciﬁ  c, 
and reproducible across different 
laboratories. It is often used to verify 
microarray ﬁ  ndings. Baranzini et al. 
identiﬁ  ed MX1 (interferon-inducible 
protein p78), a known interferon-
inducible gene, as the marker of 
treatment with IFNβ. They did not 
ﬁ  nd overall differences between 
responders and nonresponders, but 
they did, using supervised classiﬁ  cation 
methods, identify triplets of genes 
that distinguish IFNβ responders and 
nonresponders. 
Interestingly, individual and pairs of 
genes did not perform that well, and all 
three genes in a triplet were required 
for the highest accuracy (about 80%–
90%). The minimal combinatorial 
number of genes that contains the 
most predictive information is not 
available since combinations of more 
than three genes were not performed. 
Although the results were not tested on 
an independent dataset, as is frequently 
requested [22], the authors applied 
an array of cross-validation strategies 
that convincingly suggested that the 
identiﬁ  ed predictive signal was robust. 
Implications of the Study
What could Baranzini and colleagues’ 
ﬁ  ndings mean? Clearly, the most 
obvious conclusion is that the lack 
of response did not result from the 
deactivation of IFNβ. The effect of 
IFNβ on MX1, IFNAr1, and STAT2 was 
observed for two years in all patients, 
suggesting that the response did 
not depend on IFNβ bioavailability. 
Considering that PBMCs represent an 
admixture of multiple cell types, the 
most plausible explanation is a simple 
lack of shift in subcellular populations.
However, the importance of 
Baranzini and colleagues’ study lies 
not in its mechanistic insights, but 
in its clinical relevance. The careful 
design of the experiment, the use of 
reproducible real-time PCR instead 
of microarrays, the meticulous 
analysis, and the previous observations 
[15,16,17,19,20] support the notion 
that PBMCs express clinically relevant 
gene expression signatures in MS and 
probably in other organ-conﬁ  ned 
diseases. To further prove this notion 
will require a signiﬁ  cant investment in 
large studies that prospectively test the 
utility of these signatures in guiding the 
Glossary 
cDNA arrays: Microarrays in which the 
gene detectors are pieces of cDNA. 
Cross-validation: A method by which an 
available sample is split into learning and 
testing sets to test classiﬁ  ers.
Gene expression signature: Statistically 
signiﬁ  cant changes in the expression of 
multiple genes that characterize (classify) 
a biological state.
Glatiramer acetate: A synthetic protein 
made of four amino acids found in 
myelin. It is used as an immunomodulator 
drug in treating MS.
IFNβ: A cytokine that is secreted from 
ﬁ  broblasts in response to stimulation 
by a live or inactivated virus or by 
double-stranded RNA. It is used as an 
immunomodulator drug in treating MS.
Microarray: A technology that allows 
the simultaneous proﬁ  ling of the 
expression of thousands of genes 
(even whole genomes). Multiple gene 
detectors (oligonucleotides or cDNAs) 
are deposited on a slide that is hybridized 
with ﬂ  uorescently labeled samples. 
PCR (polymerase chain reaction): 
The exponential ampliﬁ  cation of a DNA 
fragment using repeated activation of a 
heat-stable DNA polymerase. 
Real-time PCR (also called one-step 
kinetic RT-PCR): A method in which the 
quantitation of the products of PCR is 
made by measuring ﬂ  uorescent emission. 
It is used for accurate quantitation of 
mRNA. 
RT-PCR (reverse transcription–
polymerase chain reaction): PCR that 
is performed on cDNA generated from 
RNA. It is used for mRNA detection and 
quantitation.
Supervised classiﬁ  cation: A process in 
which classiﬁ  ers are learned from user-
deﬁ  ned  groups (classes). 
Unsupervised classiﬁ  cation: A process 
in which classiﬁ  ers are learned without 
user-deﬁ  ned groups (classes), i.e., without 
a predeﬁ  ned training set. 
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management of MS. Only when direct 
evidence shows that therapy guided 
by markers expressed in PBMCs 
improves patient outcome will PBMC 
gene expression patterns take their 
place as biomarkers at the center stage 
of monitoring MS progression and 
response to therapy.  
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